Stimuli Technology
About the deal
Paris, November 2, 2026 – Stimuli Technology, a French medtech company specializing in the treatment of overactive bladder, announces €7 million in financing, notably marked by Seventure Partners joining its shareholder base. This transaction will enable the company to accelerate its growth in France and internationally, strengthen its clinical investments, and continue developing Tensi+, its transcutaneous tibial nerve stimulation medical device.
Founded in 2018 by Technofounders, a French deeptech venture builder, Stimuli Technology addresses a major public health challenge: overactive bladder. This syndrome affects nearly one in six adults worldwide and more than 7 million people in France. Characterized in particular by sudden, difficult-to-control urges to urinate, the condition can significantly affect patients’ quality of life.
“It was a real pleasure working with Agile Capital Markets throughout this fundraising process. Their professionalism, responsiveness and strategic guidance were invaluable in bringing this transaction to a successful close. We particularly appreciated their commitment, pragmatic approach and ability to find solutions along the way. A sincere thank you to the entire Agile team for their dedication and support as we embark on an exciting new chapter for Stimuli Technology.”
– Delphine Agullo, CEO of Stimuli Technology